Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38 Jun 17, 2019 8:00am EDT
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference May 14, 2019 4:30pm EDT
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2 Apr 22, 2019 8:00am EDT
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform Apr 02, 2019 7:00am EDT
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Mar 28, 2019 8:00am EDT
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences Mar 05, 2019 4:30pm EST
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019 Feb 27, 2019 5:00pm EST
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer Feb 19, 2019 4:30pm EST
